<DOC>
	<DOCNO>NCT01230021</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim clinical trial investigate pharmacokinetics ( rate substance distribute eliminate body ) safety profile catridecacog ( recombinant factor XIII ( rFXIII ) ) child congenital FXIII A-subunit deficiency . Young child ( 1 less 6 year old ) congenital FXIII deficiency evaluate .</brief_summary>
	<brief_title>Safety Single Intravenous Dose Recombinant Factor XIII Children With Congenital FXIII A-subunit Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Signed Informed Consent subject 's parent subject 's legally acceptable representative trial related activity . Trial related activity procedure would perform normal management subject Age 1 less 6 year old time enrolment Congenital FXIII subunitA deficiency previously document genotyping evaluate genotyping blood sample screen visit Body weight least 10 kg Known antibody FXIII Hereditary acquire coagulation disorder FXIII Asubunit congenital deficiency Platelet count ( thrombocyte ) less 50 Ã— 10^9/L ( screen visit ) Previous history autoimmune disorder involve autoantibody e.g. , systemic lupus erythematosus Previous history arterial venous thromboembolic event e.g. , cerebrovascular accident deep vein thrombosis Known suspect allergy trial product relate product Any surgical procedure 30 day prior enrolment plan surgery trial period Any disease condition , judge Investigator , could imply potential hazard subject interfere trial participation trial outcome include renal and/or liver dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>